πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
375

Quick answer

First People's Hospital has 375 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  3. Combination therapy (COMB)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  4. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  6. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial

  7. Cyclosporine A

    The First People's Hospital of Lianyungang

    Bone Marrow Failure Disorders

    phase 2 small molecule active

    1 trial

  8. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  9. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  10. DA-EPOCH

    The First People's Hospital of Lianyungang

    NHL With Hemophagocytic Lymphohistiocytosis

    phase 2 small molecule active

    1 trial

  11. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  12. DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  13. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  14. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  16. Deep-sea fish oil

    The First People's Hospital of Lianyungang

    Radiation Toxicity

    phase 2 small molecule active

    1 trial

  17. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  18. Determine the ED50 and ED95 of esketamine

    The First People's Hospital of Lianyungang

    Intrauterine Polyp

    phase 2 small molecule active

    1 trial

  19. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  20. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  21. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  22. Doxorubicin liposome

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  23. Dragon Boat Training

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  24. Drug-coated balloon angioplasty

    The First People's Hospital of Lianyungang

    Vertebral Artery Stenosis

    phase 2 other active

    1 trial

  25. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  26. Edaravone Dexborneol

    The First People's Hospital of Lianyungang

    Stroke, Ischemic

    phase 2 small molecule active

    1 trial

  27. Ejiao compound

    The First People's Hospital of Lianyungang

    Postpartum Anemia

    phase 2 small molecule active

    1 trial

  28. Endostar

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  29. Endostar

    The First People's Hospital of Lianyungang

    Brain Metastases

    phase 2 small molecule active

    1 trial

  30. Endostatins

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  31. Ensartinib

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  32. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  33. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  34. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  35. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  36. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  37. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

  38. FCN-437c+Fulvestrant

    The First People's Hospital of Lianyungang

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  39. First-line Cohort

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  40. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  41. Fluoxetine (drug)

    The First People's Hospital of Lianyungang

    Hepatobiliary Malignancy

    phase 2 small molecule active

    1 trial

  42. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. GVA + HDAC Consolidation & Gilteritinib Maintenance

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  44. Ganoderma lucidum spore

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  45. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  46. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-SchΓΆnlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  47. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  48. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

375 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.